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The link between gut microbiota and human health is well-recognized and described.
This ultimate impact on the host has contributed to explain the mutual dependence
between humans and their gut bacteria. Gut microbiota can be manipulated through
passive or active strategies. The former includes diet, lifestyle, and environment,
while the latter comprise antibiotics, pre- and probiotics. Historically, conventional
probiotic strategies included a phylogenetically limited diversity of bacteria and some
yeast strains. However, biotherapeutic strategies evolved in the last years with the
advent of fecal microbiota transplant (FMT), successfully applied for treating CDI,
IBD, and other diseases. Despite the positive outcomes, long-term effects resulting
from the uncharacterized nature of FMT are not sufficiently studied. Thus, developing
strategies to simulate the FMT, using characterized gut colonizers with identified
phylogenetic diversity, may be a promising alternative. As the definition of probiotics
states that the microorganism should have beneficial effects on the host, several
bacterial species with proven efficacy have been considered next generation probiotics.
Non-conventional candidate strains include Akkermansia muciniphila, Faecalibacterium
prausnitzii, Bacteroides fragilis, and members of the Clostridia clusters IV, XIVa, and
XVIII. However, viable intestinal delivery is one of the current challenges, due to their
stringent survival conditions. In this review, we will cover current perspectives on the
development and assessment of next generation probiotics and the approaches that
industry and stakeholders must consider for a successful outcome.
Keywords: FMT, next generation probiotics, bacterial consortium, synthetic community, CDI
INTRODUCTION
The gut microbiota plays a significant role in human health, participating in several functions
beneficial to the host (Patel and DuPont, 2015; Kristensen et al., 2016). It has been implicated
in preventing pathogen colonization (Hand, 2016), shaping our immune system (Round and
Mazmanian, 2009; Patel and DuPont, 2015; Macpherson et al., 2017), stimulating the production
of gastrointestinal hormones (Saulnier et al., 2013), and regulating brain behavior (De Palma et al.,
2014, 2017) through production of neuroactive substances (Steenbergen et al., 2015; Kristensen
et al., 2016).
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Additionally, the gut microbiota has been involved in the
fermentation of non-digestible carbohydrates reaching the colon.
This process leads to the production of short chain fatty acids
(SCFAs), which elicit health benefits (den Besten et al., 2013).
The human gut microbiota can be manipulated through either
passive or active processes. Passive factors include hygiene,
lifestyle, and diet. For instance, primary colonizers of the gut
involved in the immune development are shifted by sanitary
practices (Zhou, 2016). In addition, dietary constituents can
promote phylogenetic variations in the microbiota (Graf et al.,
2015). In this context, prebiotics are defined as “a substrate
that is selectively utilized by host microorganisms conferring a
health benefit” (Gibson et al., 2017). Prebiotics act as growth
substrates (Patrascu et al., 2017) to enhance the activity of
bacterial genera (Scott et al., 2015) such as bifidobacteria and
butyrate-producing clostridia (Rivière et al., 2016). SCFA and
vitamins resulting from the fermentation of these components
are crucial for human health (Graf et al., 2015). In terms of
lifestyle factors, physical activity is known to positively impact
the diversity of gut microbiota. In fact, gut microbiota of athletes
is more diverse than that of non-athletic subjects (Clarke et al.,
2014). Amongst the active processes manipulating microbiota
composition are antibiotics and probiotics. Antibiotic use has
been linked to dysbiosis (Langdon et al., 2016), even leading
to low diversity, evenness, and taxonomic richness (Dethlefsen
and Relman, 2010; Francino, 2016). Moreover, presence and
expression of microbial genes are altered following antibiotic
therapy (Reijnders et al., 2016). These detrimental outcomes
may lead to decreased SCFA, glycolysis, vitamin production,
homeostasis of the immune system, and impaired protection
against pathogens (Guarner and Malagelada, 2003). As a result,
antibiotic associated diarrhea (AAD) and recurrent infectious
diseases like Clostridium difficile infection (CDI) may occur
(Francino, 2016).
On the other side of the spectrum are probiotics, which
can affect the host either directly or through their products,
or even influence the activity of resident bacteria in the host
(Scott et al., 2015). Probiotics are defined as “live microorganisms
which when administered in adequate amounts confer a health
benefit on the host” (WHO/FAO, 2006; Hill et al., 2014).
The effect of probiotics in preventing metabolic syndromes
such as obesity, type 2 diabetes (Kasin´ska and Drzewoski,
2015), and dyslipidemia has been reported (Asemi et al.,
2013). For instance, administration of Bifidobacterium (Yin,
2010; Chen et al., 2011; Plaza-Diaz et al., 2014; Reichold
et al., 2014; Savcheniuk et al., 2014; Wang et al., 2014) and
Lactobacillus species reduced body weight gain and adipose tissue
in mice fed high-fat diet through stimulation of adiponectin
production (Kim et al., 2013; Kobyliak et al., 2016). In
addition, lactobacilli have been proven to have therapeutic effects
in different pathologies (Di Cerbo et al., 2016). Moreover,
probiotics regulate the mucosal immune response (Klaenhammer
et al., 2012), improving the activity of macrophages (Sang,
2010) and changing the expression of the genes associated.
Even though these outcomes depend on specific bacteria and
strains, probiotics may interact with TLR and downregulate
the expression of NF-κB and pro-inflammatory cytokines
(Ng et al., 2009; Plaza-Diaz, 2014). For instance, peptides
of microbial anti-inflammatory molecules (MAMs) that are
found in the Faecalibacterium prausnitzii supernatant inhibit
the NF-κB pathway in vitro and in vivo (Breyner et al., 2017),
confirming the anti-inflammatory and therapeutic properties
of F. prausnitzii (Martín et al., 2014). These properties and
protective effects of F. prausnitzii were identified in different
models such as dinitrobenzene sulfate (DNBS)-induced colitis
model, dextran sodium sulfate (DSS)-induced colitis (Breyner
et al., 2017), and 2,4,6-trinitrobenzenesulfonic acid (TNBS)-
induced acute colitis in mice (Miquel et al., 2015). Additionally,
levels of anti-inflammatory cytokines and immunoglobulins,
immune cell proliferation, and production of proinflammatory
cytokines produced by the T cells may be modulated following
probiotic supplementation (Miettinen et al., 1996; Nazemian
et al., 2016). Furthermore, probiotics can be alternative strategies
for inflammatory disorders, as they upregulate the production of
CD4+Foxp3+ regulatory T cells (Tregs) (Kwon et al., 2010; Yan
and Polk, 2011).
Different effects on the immune function may be species-
and strain-related (Klaenhammer et al., 2012). It has been
reported that probiotics have therapeutic effect on the central
nervous system by reducing the intestinal inflammation. In
this way, the regulation of HPA axis and the activity of the
neurotransmitters may be improved (Wallace and Milev,
2017). Probiotics from Bifidobacterium and Lactobacillus
genera are usually delivered through fermented products
such as yogurts, milk, and cheeses, or they can be delivered
as food supplements (Besseling-van der Vaart et al.,
2016).
MONOSTRAIN AND MULTISTRAIN
PROBIOTICS
Probiotics have been categorized into monostrain or
multistrain/multispecies products (Timmerman et al., 2004).
Different studies have confirmed positive effects on health
when multistrain probiotics are used, due to the symbiosis
among strains (Timmerman et al., 2004). Strains in multispecies
probiotics can be from different genera. For instance, the efficacy
of the multispecies probiotic consortium VSL#3 (Streptococcus
thermophilus, Eubacterium faecium, Bifidobacterium breve,
Bifidobacterium infantis, Bifidobacterium longum, Lactobacillus
acidophilus, Lactobacillus plantarum, Lactobacillus casei, and
Lactobacillus delbrueckii subspecies bulgaricus) was proven
for the treatment of ulcerative colitis (Venturi et al., 1999;
Timmerman et al., 2004). Besides, VSL#3 supplementation
in women with gestational diabetes mellitus (GDM) may
help regulate inflammatory markers and positively influence
glycemic control (Jafarnejad et al., 2016). In addition, Chapman
et al. (2011) described that probiotic mixtures were more
effective than single-strain probiotics in inhibiting pathogen
growth and atopic dermatitis, suggesting further application
on other diseases like IBD. Another multispecies probiotic
called Ecologic R©Tolerance/SyngutTM was developed using
four different probiotic strains (Bifidobacterium lactis W51,
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L. acidophilus W22, L. plantarum W21, and Lactococcus
lactis W19). Strains of this consortium have been proven to
strengthen the gut barrier function, have beneficial effects on
post-immunological induced stress, inhibit Th2, and stimulate
IL-10 levels, thus providing beneficial effects in patients with
food intolerance (Besseling-van der Vaart et al., 2016). Moreover,
a multispecies probiotic consortium, Ecologic AAD (B. bifidum
W23, B. lactis W18, B. longum W51, E. faecium W54, L.
acidophilus W37 and W55, L. paracasei W72, L. plantarum
W62, L. rhamnosus W71, and L. salivarius W24), reduced
diarrhea-like bowel movements when administered in healthy
volunteers taking amoxicillin (Koning et al., 2008). Multispecies
probiotics also prevented rise in fasting plasma glucose (FPG),
to decrease high sensitivity C-reactive protein (hs-CRP), and
to increase plasma glutathione (GSH) in diabetic patients
(Asemi et al., 2013). van Minnen et al. (2007) provided evidence
that manipulation of the intestinal flora with multispecies
probiotics reduced bacterial translocation, morbidity and
mortality in a rat model of acute pancreatitis. Furthermore,
multispecies probiotics rapidly relieved IBS symptoms and
shifted the microbiota composition (Yoon et al., 2013).
According to these results, combining specific probiotic
effects from diverse strains can lead to an additive and more
synergetic multispecies probiotic consortium (Timmerman et al.,
2007).
However, the phylogenetic origin of probiotics is currently
limited to conventional formulations of Bifidobacterium,
Lactobacillus species and other lactic acid bacteria (LAB)
(Govender et al., 2013) or yeast strains. This may decrease
the probiotic effectiveness in the prevention or therapy of
diseases entailing severe dysbiosis. Hence, a functionally and
phylogenetically diverse probiotic product may be desirable
when alterations in the gut microbiota composition are
present (Marotz and Zarrinpar, 2016). For instance, CDI and
recurrent CDI are major medical conditions that need urgent
treatment when conventional antibiotics fail. As a result,
development of complex communities with targeted functions is
needed.
THE DILEMMA OF FECAL MICROBIOTA
TRANSPLANT (FMT)
Fecal microbiota transplant (FMT) or fecal bacteriotherapy
is an alternative strategy successfully used for the treatment
of CDI (Kelly, 2013). Severe antibiotic therapy and CDI
trigger dysbiosis, reducing diversity and functionality of the
gut endogenous microbiota (Brandt, 2012). In this case,
C. difficile spores can germinate, colonize, and thrive in
the gut. Treatment of CDI requires additional antibiotics,
increasing the risk of recurrent CDI (rCDI) after cessation of
treatment, as a result of the dysbiosis caused by antibiotic
therapy (Becattini et al., 2016; Francino, 2016), due to
infection with the original strain (Barbut et al., 2000;
Marsh et al., 2012) or re-infection caused by a different
strain (Johnson et al., 1989; Kelly, 2009; Figueroa et al.,
2012).
Poor colonization resistance from the gut microbiota and
the patient’s poor immune response further contribute to CDI
risk (Pérez-Cobas et al., 2015). Recurrent CDI risk is 10–20%
after initial CDI (Surawicz et al., 2013), and it increases to
45% after a first relapse, and to 60% for those with two or
more recurrences (Bartlett, 1990). However, FMT can resolve
both CDI and rCDI (Bakken, 2009), with a success rate of
90% when further antibiotic treatments fail (Youngster et al.,
2014; Rao and Safdar, 2015). Given the success of FMT, it
is now being considered as potential treatment for disorders
such as ulcerative colitis (Shi et al., 2016), irritable bowel
syndrome (Distrutti et al., 2016), and metabolic syndrome
(Hartstra et al., 2015). For instance, FMT induced remission in
patients with active ulcerative colitis (Moayyedi et al., 2015),
potentially as a result of the introduction of normal flora and
the subsequent correction of the imbalance in the microbiota
caused by the disease (Bakken et al., 2011). The complexity
of the fecal sample can be the key factor behind the positive
shift in the microbiota composition generated by the FMT
(Marotz and Zarrinpar, 2016). Thus, diversity of the donor
microbiome may be crucial (Leszczyszyn et al., 2016). Indeed,
some patients do not respond to FMT, probably because only
specific bacterial phylotypes can be therapeutic when effectively
transferred (Vermeire et al., 2015). Hence, FMT efficacy for
treating gastrointestinal disorders is controversial (Sbahi and
Di Palma, 2016). Adverse effects after FMT include nausea,
vomit, fever, abdominal pain, and diarrhea (Vermeire et al., 2015;
Pigneur and Sokol, 2016). Data for long-term effects of FMT
is lacking, but theoretically, any disease phenotype from the
donor can be transferred to the patient (Sbahi and Di Palma,
2016). This could be expected, as the uncharacterized nature
of FMT may result in undetected or unmonitored risk factors
such as viruses, pathogens or even allergens being passed to
the FMT recipient, causing disease. To overcome this problem,
Petrof et al. (2013) developed a synthetic bacteria cocktail
with characterized nature to substitute FMT. Alternatively, a
thorough pre-screening should be performed on the donor
before the actual procedure of the FMT. Thus, the French
Group of Fecal microbiota Transplantation (FGFT) was created
to secure and evaluate the practice in this field (Sokol et al.,
2016). Despite having experience treating CDI, FMT is not yet
the top treatment choice of physicians (Zipursky et al., 2014).
However, the majority of gastroenterologists and physicians
in metropolitan areas were supportive to the idea of creating
a fecal transplantation center, and a high percentage of the
physicians would refer their patients to those centers (Jiang et al.,
2013).
ALTERNATIVES FOR FECAL
MICROBIOTA TRANSPLANT (FMT)
Additional microbiome therapeutics using characterized
microbial communities of selected fecal bacteria could be
developed to replace FMT, and yield the desired outcome
(Sbahi and Di Palma, 2016). For instance, Petrof et al. (2013)
described a stool substitute constituted by 33 different purified
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TABLE 1 | Strains composing the RePOOPulate consortium.
Composition of Stool Substitute (RePOOPulate)
Acidaminococcus intestinalis
Bacteroides ovatus
Bifidobacterium adolescentis (two different strains)
Bifidobacterium longum (two different strains)
Blautia producta
Clostridium cocleatum
Collinsella aerofaciens
Dorea longicatena (two different strains)
Escherichia coli
Eubacterium desmolans
Eubacterium eligens
Eubacterium limosum
Eubacterium rectale (four different strains)
Eubacterium ventriosum
Faecalibacterium prausnitzii
Lachnospira pectinoshiza
Lactobacillus casei/paracasei
Lactobacillus casei
Parabacteroides distasonis
Raoultella sp.
Roseburia faecalis
Roseburia intestinalis
Ruminococcus torques (two different strains)
Ruminococcus obeum (two different strains)
Streptococcus mitis
intestinal bacteria isolated from a healthy donor (Table 1),
to treat rCDI. In this study, the synthetic bacterial mixture
was infused through the colon of the infected patient
causing a change in the stool microbial profile. Major shifts
reflecting the isolates of the synthetic mixture were still
detectable 6 months after treatment. Thus, the concept of
“RePOOPulate” the gut microbiome was coined. Authors of
the study suggested that using a synthetic stool substitute
may be an effective method to replace the use of FMT for
treating rCDI. Although further validation is needed, complete
resolution of the infection was achieved. Several advantages
of this synthetic stool substitute can be highlighted. The
composition of the administered bacterial cocktail is accurately
characterized, facilitating registration. Further, assembly of
the synthetic bacterial cocktail is highly reproducible enabling
standardization and upscaling. In addition, patient safety
can be guaranteed, because the bacterial mixture can be
rendered pathogen- and virus-free (Petrof et al., 2013). These
data suggest that a multi-species community such as that in
the RePOOPulate study, can be more effective than single-
strain probiotics or mixed cultures of probiotic species. This
can be because the RePOOPulate community preserved its
structure and thus successfully colonized a new environment
(Petrof et al., 2013). Moreover, RePOOPulate consisted of a
more phylogenetically diverse community including strains
with beneficial health effects that can be candidates for next
generation probiotics.
NEXT GENERATION PROBIOTICS
Looking at its internationally recognized definition, probiotics
are live microorganisms that, when administered in adequate
numbers, confer health benefits on the host. Probiotics are
usually isolated from our commensal gut bacteria, but cannot
be given the definition of probiotics until their stability, content,
and health effect are characterized (Sanders, 2008). Probiotics
are thought to improve the balance in the host, prevent
disturbances, and decrease the risk of pathogen colonization
(Goldenberg et al., 2013). They have been referred to as
functional foods or beneficial bacteria, and they have been
considered for the prevention and treatment of C. difficile-
associated diarrhea (CDAD) (Goldenberg et al., 2013). Probiotics
can be found as capsules or food supplements in health food
stores and supermarkets (Goldenberg et al., 2013). Pattani
et al. (2013) reported that Lactobacillus-based formulations
combined with antibiotics reduced the risk of AAD and CDI.
They however, suggested that larger studies are needed to
decide on the use of probiotic/antibiotic combination as a
therapy over the single species probiotic (Pattani et al., 2013).
Furthermore, findings from randomized control trials (RCTs)
and meta analyses suggest that there is moderate evidence
on the ability of probiotics to prevent primary CDI (people
at risk of CDI), but there is no enough evidence suggesting
the probiotics can prevent secondary CDI (recurrent CDI)
(Evans and Johnson, 2015). There are still some evidence gaps
for the use of probiotics in the prevention of CDI such as
the interaction between specific classes of antibiotics with the
probiotics used on CDI risk, the bacterial taxa that provides
the best efficacy in the prevention of CDI, and the use of
probiotics in immunocompromised or critically ill patients (Rao
and Young, 2017). Hence, future RCT should consider these
different concerns (Rao and Young, 2017). Besides, probiotics
impact the gut-brain axis.
For example, Bifidobacterium longum NC3001 had beneficial
effects on psychiatric comorbidities, which in turn could
temporarily improve the quality of life in IBS patients, indicating
that this probiotic reduces limbic reactivity (Pinto-Sanchez et al.,
2017).
Overall, classical probiotics show limited effects on
the human gut microbiota seeking the need for a better
selection and formulation of bacterial strains (Neef and
Sanz, 2013). Results from previous studies show promising
outcomes in the treatment or prevention of diverse
metabolic and inflammatory diseases by specific bacteria
(Neef and Sanz, 2013). Those probiotics encompass
species different from Lactobacillus and Bifidobacterium
(Cani and Van Hul, 2015; Patel and DuPont, 2015).
Nevertheless, the gut microbiome is a complex community,
which makes it difficult to define the host–microbe
interaction.
The United Nations Food and Agriculture organization
(FAO) definition of probiotics is broad, allowing flexibility in
terms of the phylogenetic origin of probiotics. Information
generated from previous studies assisted in the selection of next
generation probiotics, which include members from Clostridium
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clusters IV, XIVa and XVIII, F. prausnitzii, Akkermansia
muciniphila, Bacteroides uniformis (Neef and Sanz, 2013; Patel
and DuPont, 2015), Bacteroides fragilis (Round et al., 2011),
and Eubacterium hallii (Udayappan et al., 2016). These next
generation probiotics were evaluated in preclinical trials and
yielded positive outcomes for inflammatory and metabolic
disorders (Neef and Sanz, 2013; Patel and DuPont, 2015). In
addition, new techniques are required for the development
of new probiotic products containing strains from human
origin. This is to say, these strains must come from the major
groups of the intestinal microbiota, they have to be defined
to have a safe status and proven to have potential beneficial
effects (Martín et al., 2017). In the following sections, we will
discuss some of the most promising bacterial species that are
currently under consideration for being used as next-generation
probiotics.
Faecalibacterium prausnitzii
Faecalibacterium prausnitzii is an extreme oxygen sensitive (EOS)
bacterium (Martín et al., 2017) belonging to the Clostridium
cluster IV, and it accounts for 3–5% of the total fecal bacteria,
and it is one of the predominant groups in the human feces
(Breyner et al., 2017). Quévrain et al. (2016) reported low
proportions of this species in the fecal and mucosa-associated
microbiome in Crohn’s disease (CD). F. prausnitzii may possess
in vivo and in vitro anti-inflammatory effects. F. prausnitzii
may possess in vivo and in vitro anti-inflammatory effects.
Breyner et al. (2017) confirmed the anti-inflammatory properties
of MAM, and their ability to reduce Th1 and Th17 pro-
inflammatory cytokines in Mesenteric Lymphatic Node (MLN)
and colon tissues in both DNBS and DSS colitis model.
MAM was also able to improve TGFβ cytokine which affects
NF-κB activation in DNBS model thus protecting the host
and decreasing intestinal inflammation (Breyner et al., 2017).
In addition, F. prausnitzii can induce the Clostridium-specific
IL-10-secreting regulatory T cell subset, present in several
human colonic cells. Its capacity for lowering IL-12 and IFNγ
production indicates that the interaction between F. prausnitzii
and the host shape and maintain the gut barrier immune
function (Quévrain et al., 2016). In this way, anti-inflammatory
molecules from F. prausnitzii may be used as targeted anti-
inflammatory drugs for CD. Moreover, MAM could function as
a CD biomarker, predicting loss of F. prausnitzii functionality.
However, further research should be conducted to elucidate the
MAM production mechanisms, before considering it for CD
management. Sokol colleagues reported that low proportions
of F. prausnitzii on a resected ileal Crohn’s mucosa were
associated with CD recurrence after 6 months. In addition, the
oral administration of live F. prausnitzii or its supernatant in
mice could reduce the severity of trinitrobenzene sulfonic acid
(TNBS) colitis and correct the associated dysbiosis (Sokol et al.,
2008). The results from this study suggest that F. prausnitzii
can be considered as a promising probiotic candidate for
the treatment of pathologies characterized by chronic gut
inflammation (Sokol et al., 2008). Besides, all F. prausnitzii
strains have proven anti-inflammatory properties, which allows
them to further be tested in murine models to determine their
beneficial effects before moving to human trials (Martín et al.,
2017).
Akkermansia muciniphila
Recent evidence shows that there is a link between the altered
gut microbiota and metabolic diseases like obesity, diabetes
mellitus, and cardiovascular disease (Schneeberger et al.,
2015; Dao et al., 2016; Li et al., 2016). Higher abundance of
A. muciniphila, a mucin degrading microbe, was associated
with healthier metabolic status. Everard et al. (2014) and
Schneeberger et al. (2015) studied the effects of high fat
diet on metabolic parameters and the gut microbiota
composition over time, and they found that A. muciniphila
was decreased. The negative impact on A. muciniphila was
associated with expression of lipid metabolism, inflammatory
markers in adipose tissue, and different parameters like
increased blood glucose, insulin resistance and plasma
triglycerides (Schneeberger et al., 2015). This prompted
the research toward investigating the putatively positive
role of A. muciniphila in adipose tissue homeostasis and
metabolism. Dao et al. (2016) assessed clinical parameters
and A. muciniphila abundance before and after a 6-week
calorie restriction period, followed by stabilization diet. The
results of this intervention study indicate that the higher
abundance of A. muciniphila at baseline was associated with
improvement in blood glucose homeostasis, lipid profile,
and body fat distribution after the intervention. Thus,
A. muciniphila can be used as a prognostic tool for the
success of diet interventions (Dao et al., 2016). Moreover, Li
et al. (2016) reported that administration of A. muciniphila
could reverse the atherosclerotic lesions, improve metabolic
endotoxemia-induced inflammation, and ultimately restore the
gut barrier.
Bacteroides fragilis and Bacteroides
uniformis
Bacteroides species are commensal bacteria that represent 25%
of our gut bacterial population. They are gram negative,
anaerobic, bile resistant, and non-spore forming bacteria.
Bacteroides can be passed from the mother to the child
during vaginal delivery, thus becoming primary colonizers
of the gut. When retained in the gut, Bacteroides act as
commensals and can be beneficial for the host (Wexler, 2007).
The most common isolate from the clinical specimens is
B. fragilis, which is the most virulent Bacteroides species (Wexler,
2007).
Bacterial colonization of the gut can greatly affect the
immune system, either through the direct host–bacteria
interaction, or by molecules produced by our commensal
bacteria. B. fragilis produces polysaccharide A (PSA), which
is an immunomodulatory molecule that activates the T-cell
dependent immune responses (Troy and Kasper, 2010). Those
responses are involved in the development and homeostasis of
the host immune system (Troy and Kasper, 2010). Furthermore,
Round et al. (2011) demonstrated that B. fragilis activates
Toll-like receptor (TLR) pathways. This occurs because
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PSA signals through TLR2 on Foxp3+ (forkhead box P3)
regulatory T cells to boost immunologic tolerance. As a
result, PSA can be considered as a model symbiosis factor,
because it preserves the balance between T cell types and
maintains the immune system homeostasis (Round et al.,
2011).
As for Bacteroides uniformis (B. uniformis) CECT 7771, it is
considered a potential probiotic strain originally isolated from
the feces of healthy breastfed infants. Oral administration of
this specific strain in high fat diet-fed mice improved lipid
profile, reduced glucose insulin and leptin levels, increased
TNF-α production by dendritic cells (DCs) in response to LPS
stimulation, and increased phagocytosis (Gauffin Cano et al.,
2012). Thus, administration of B. uniformis CECT 7771 can
ameliorate metabolic disorder and immunological dysfunction
related to intestinal dysbiosis in obese mice (Gauffin Cano et al.,
2012; Yang et al., 2016). Furthermore, acute administration of
this strain to mice did not promote adverse effects on health
status or food intake, and there was no bacteria translocation
to blood, liver, or lymph nodes. This indicates that there are no
safety concerns for this strain in mice, but further investigation
should be completed in humans (Fernández-Murga and Sanz,
2016).
Eubacterium hallii
Eubacterium hallii is an important anaerobic butyrate-
producer resident in our gut, which influences the intestinal
metabolic balance (Engels et al., 2016). Butyrate has been
proposed to lower mucosal inflammation and oxidative
status, strengthen the epithelial barrier function, and
modulate intestinal motility in addition to being an energy
source for colonocytes (Canani et al., 2011). E. hallii
can yield propionate from a broad range of substrates.
This versatility may enhance the host–gut microbiota
homeostasis (Engels et al., 2016). Moreover, administration
of E. hallii in obese and diabetic db/db mice increased energy
metabolism and improved insulin sensitivity. However,
increasing dosage of E. hallii did not impact body weight
or food intake, indicating that this strain can a safe and
effective alternative for insulin sensitivity (Udayappan et al.,
2016).
COCKTAILS OF Clostridium CLUSTER IV
AND XIVA MEMBERS
As previously described, Tregs can regulate immune homeostasis
and serve as a therapeutic target for different gut inflammatory
disorders. Induction of the colonic Tregs is dependent on special
properties of our commensal bacteria. Clostridium spp. belonging
to clusters IV and XIVa (also known as Clostridium leptum
and coccoides groups, respectively) are exceptional inducers of
Tregs in the colon and can be considered as therapeutic options
for IBD and allergies (Atarashi et al., 2011). Previous work
indicated that a cocktail of strains isolated for the human
gut microbiota can be more effective than a single strain in
preventing or treating disease. Thus, Atarashi et al. (2013)
isolated 17 strains belonging to Clostridia clusters XIVa, IV,
and XVIII from a human fecal sample, which were effective
in Treg cell differentiation and accumulation in mouse colon.
Authors proposed that the SCFAs produced by this community
influenced the expression of Foxp3, a key gene controlling Treg
cell development (Atarashi et al., 2013). Incidentally, Clostridia
clusters XIVa and IV are decreased in fecal samples from patients
with inflammatory bowel disease (IBD), and thus the cocktail of
the 17 strains could potentially reverse this dysbiosis (Atarashi
et al., 2013).
INDUSTRIAL APPLICATIONS AND
INTERESTS
Current Developments
Since the manipulation of the gut microbiota has been proven
to be promising to prevent and treat different diseases,
pharmaceutical and food industries would be interested in
the potential therapeutic approaches described before. For
instance, Seres health and Rebiotix companies are working on
developing a defined microbial cocktail and a standardized
commercially prepared FMT, respectively. These therapeutic
approaches are intended to treat CDI, and that can be used
as an alternative for FMT. Synthetic microbial communities
designed for transplants are expected to meet production, mode
of action and safety standards (Orenstein et al., 2015; van der
Lelie et al., 2017). For instance, Seres health developed SER-
109, a novel biological agent proposed to restore the balance
in the gut microbiome, promoting resistance to pathogenic
invaders like C. difficile (Khanna et al., 2016). Seres health
also developed SER-287 for the treatment of IBD and in
specific ulcerative colitis (Inflammatory Bowel Disease | Seres
Therapeutics, 2017). Rebiotix commercially developed RBX2660,
a mix of live human microbes for effective treatment of recurrent
CDI (Ramesh et al., 2016). Moreover, other formulations
including strains belonging to Clostridia classes IV and XIVa
were designed to modulate the immune response (Atarashi
et al., 2013). The original community of 17 strains (VE202) was
developed by Vendanta Biosciences and Johnson and Johnson,
and has provided an effective treatment for autoimmune
disorders (Reardon, 2014; Ratner, 2015; van der Lelie et al.,
2017).
Technical Challenges
Several challenges concerning the stability of the probiotic during
the probiotic production are still unsolved. Microorganisms
require strict conditions to grow, such as specific nutritional
media and environmental conditions (suitable temperature,
pH, water activity, oxygen content, among others). The
product manufacturing and storage processes may impact the
viability of the bacterial strains, influencing probiotic stability
and properties. In addition, it is fundamental to consider
the viability of the probiotics after consumption. Bacterial
strains should remain viable at sufficient numbers through the
gastrointestinal tract (GIT) passage. Therefore, the selection
of optimal culture medium and cell protectants is crucial
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to enhance the efficacy of the probiotic product. Moreover,
as most probiotic strains are strict anaerobes or facultative
anaerobes, oxygen permeation into carriers should be reduced,
or oxygen scavengers should be introduced to reduce the redox
potential (Shah et al., 2010). Probiotic bacteria can also be
protected by microencapsulation, which has been proposed to
improve the stability of the strains and can adapt to the GIT
conditions (Heidebach et al., 2012). Nowadays, yogurts and
fermented milk are the best-established vehicles for probiotics
in the market. However, some probiotic strains are sensitive
to the different conditions in fermented products, like oxygen
and pH, which can, in turn, affect the stability of probiotics
through post-acidification during their storage in the fridge.
To minimize this phenomenon, strains that lack the ability
to post-acidify should be selected (Damin et al., 2008). As a
result, this can cause an economic burden for manufacturers,
limiting the addition of probiotics in different products
(Gueimonde and Sánchez, 2012). Furthermore, manufacturing
the probiotic product in a reproducible manner is a critical
aspect (Paulo Sousa e Silva and Freitas, 2014). Several attempts
to fix the number of viable probiotic strains throughout the
products (Shah et al., 2010) have been attempted, to no
avail.
Regulatory Challenges
Probiotics are classified in different categories across countries.
Their names and use as functional foods may vary according to
different systems. For instance, probiotics fall in the Qualified
Presumption of Safety (QPS) list provided by the European
Food Safety Authority (EFSA) and referred to as functional
foods since there was no legal definition for probiotics. The
market for probiotics as functional foods expanded, as a result
of probiotic food products like yogurts and fermented milk
(Baldi and Arora, 2015), containing conventional LAB. The QPS
list is periodically updated according to the safety assessment
of the biological products recommended to be added, and not
all can be approved (Scientific Opinion on The Maintenance
of The List of QPS Biological Agents Intentionally Added
to EFSA Panel on Biological Hazards (BIOHAZ), 2013; Ricci
et al., 2017). A similar system applies in the United States
as Generally Recognized as Safe (GRAS) products should be
approved by the FDA. However, if a probiotic is used as a dietary
supplement in the United States, then it is considered as “food”
and should be regulated by the Dietary Supplement Health and
Education Act (DSHEA). If the probiotic was considered to have
therapeutic purpose, the probiotic drug should be proven to
be safe and effective to be approved by the FDA. Nevertheless,
for both the FDA and EFSA, probiotics cannot be used in
health claims. On the other hand, Japan acts as a global market
leader, where probiotics are considered as both foods and drugs.
According to the Japanese regulations, probiotic products are in
different category than foods and Foods for Specific Health Uses
(FOSHU). Efficacy claims for probiotic products are prohibited
on the labeling until the product gets the permission from the
Ministry of Health and Welfare (MHLW) to be considered
FOSHU, for which efficacy and safety validation is mandatory.
FOSHU categorizes the food claims according to the scientific
evidence and the strength of the supporting data provided.
The government then divided the FOSHU health claims into
subcategories, in which their effect could be in GIT, metabolism,
cholesterol moderation, or bone health. Japanese regulations also
approve new health claims on a regular basis (Baldi and Arora,
2015).
As the definition and classification of probiotics by regulatory
agents throughout the world is different, the status of probiotic
products is still uncertain. Thus, reservations about probiotic
products claims may arise among regulatory bodies, producers,
and consumers. Since the probiotic concept is invading the
world, further investigation for probiotic traits is needed.
Moreover, most probiotics only include LAB, which possess
limited phylogenetic diversity and functionality. Hence, critical
update of the screenings required by regulatory agents is urgently
needed.
Medical Application
Despite the different studies and outcomes of FMT, FDA approval
in North America has not been granted. At the beginning, FMT
was considered as investigational new drugs (INDs), and FDA
authorization was mandatory. Currently, patients unresponsive
to standard antibiotic CDI therapies can opt for FMT after
completing an informed consent, where they are notified that
FMT is still under investigation. However, SERES 109 and
RBX2660 have been granted the Orphan Drug designation by
the FDA (Rebiotix Media, 2015; Seres Therapeutics, 2015). As
for the EMA in Europe, the use of FMT for the treatment of
CDI has not been yet regulated (van Nood et al., 2014; Lowes,
2016). Yet, FMT is regularly applied to curb infections across
Europe, and it is considered in clinical trials for many other
pathologies. In the search for safe FMT alternatives, research on
microbiotic medicinal products (MMP) is in full development
and novel applications are continuously being considered. These
MMP developments require novel views and strategies from
the scientific world, the industry, the medical field, and the
regulatory bodies. In this context, platforms like the Pharmabiotic
Research Institute have been created, to facilitate discussion
between different stakeholders (Pharmabiotic Research Institute,
2017). Overall, additional research needs to be conducted
before using FMT alternatives containing characterized microbial
communities and next generation probiotics, to guarantee their
safety and reproducible efficacy.
CONCLUSION
FMT may be replaced with a characterized multispecies bacterial
mixture that can be safer, free of allergens or viruses, and
capable of treating CDI. With the current in vitro and in vivo
data, next generation probiotics hold promise to treat diverse
medical conditions, and they can be more effective than
single or multi strains of the commercial probiotics. Moreover,
several different strains with proven health benefits can also
be considered candidates for next generation probiotics and
other microbiota-based drugs. However, additional research is
required for an increased understanding of the interactions
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among those strains, aiming at producing a successful therapeutic
formulation. Research should be conducted to demonstrate
whether these probiotics can be applicable to humans, as safety
assessments have only been completed in animals. Effective
carriage of bacterial strains in food matrices is critical for
survival. Thus, optimisation of the growing conditions, and
even encapsulation must be considered to promote delivery and
release of the live product in the colon. The development of next
generation probiotics and MMPs hold promise for innovation
in both the food/feed sector and the pharmaceutical industry.
A close interaction between academia, industry and regulatory
agencies is essential for developing safe and health-promoting
products, as both prophylactic and therapeutic strategies.
AUTHOR CONTRIBUTIONS
Conceived and designed the review: REH, EH-S, and TVW.
Funding acquisition: TVW. Wrote the paper: REH. Reviewed the
manuscript: REH, EH-S, and TVW.
ACKNOWLEDGMENT
The research leading to these results has received funding from
the People Program (Marie Curie Actions) of the European
Union’s Seventh Framework Program FP7/2007–2013/under
REA grant agreement n◦ 606713.
REFERENCES
Asemi, Z., Zare, Z., Shakeri, H., Sabihi, S.-S., and Esmaillzadeh, A. (2013). Effect
of multispecies probiotic supplements on metabolic profiles, Hs-CRP, and
oxidative stress in patients with Type 2 diabetes. Ann. Nutr. Metab. 63, 1–9.
doi: 10.1159/000349922
Atarashi, K., Tanoue, T., Oshima, K., Suda, W., Nagano, Y., Nishikawa, H., et al.
(2013). Treg induction by a rationally selected mixture of Clostridia strains from
the human microbiota. Nature 500, 232–236. doi: 10.1038/nature12331
Atarashi, K., Tanoue, T., Shima, T., Imaoka, A., Kuwahara, T., Momose, Y., et al.
(2011). Induction of colonic regulatory T cells by indigenous Clostridium
species. Science 331, 337–341. doi: 10.1126/science.1198469
Bakken, J. S. (2009). Fecal bacteriotherapy for recurrent Clostridium difficile
infection. Anaerobe 15, 285–289. doi: 10.1016/j.anaerobe.2009.09.007
Bakken, J. S., Borody, T., Brandt, L. J., Brill, J. V., Demarco, D. C., Franzos,
M. A., et al. (2011). Treating Clostridium difficile infection with fecal microbiota
transplantation. Clin. Gastroenterol. Hepatol. 9, 1044–1049. doi: 10.1016/j.cgh.
2011.08.014
Baldi, A., and Arora, M. (2015). Regulatory categories of probiotics across the
globe: a review representing existing and recommended categorization. Indian
J. Med. Microbiol. 33(Suppl.), 2–10. doi: 10.4103/0255-0857.150868
Barbut, F., Richard, A., Hamadi, K., Chomette, V., Burghoffer, B., and Petit, J.-C.
(2000). Epidemiology of recurrences or reinfections of Clostridium difficile-
associated diarrhea. J. Clin. Microbiol. 38, 2386–2388.
Bartlett, J. G. (1990). Clostridium difficile: clinical considerations. Clin. Infect. Dis.
12(Suppl. 2), S243–S251. doi: 10.1093/clinids/12.supplement_2.s243
Becattini, S., Taur, Y., and Pamer, E. G. (2016). Antibiotic-induced changes in the
intestinal microbiota and disease. Trends Mol. Med. 22, 458–478. doi: 10.1016/
j.molmed.2016.04.003
Besseling-van der Vaart, I., Heath, M. D., Guagnini, F., and Kramer, M. F. (2016).
In vitro evidence for efficacy in food intolerance for the multispecies probiotic
formulation Ecologic R© Tolerance (SyngutTM). Benef. Microbes 7, 111–118.
doi: 10.3920/bm2015.0051
Brandt, L. J. (2012). Fecal transplantation for the treatment of Clostridium difficile
infection. Gastroenterol. Hepatol. 8, 191–194.
Breyner, N. M., Michon, C., de Sousa, C. S., Vilas Boas, P. B., Chain, F., Azevedo,
V. A., et al. (2017). Microbial anti-inflammatory molecule (MAM) from
Faecalibacterium prausnitzii shows a protective effect on DNBS and DSS-
induced colitis model in mice through inhibition of NF-κB pathway. Front.
Microbiol. 8:114. doi: 10.3389/fmicb.2017.00114
Canani, R. B., Costanzo, M. D., Leone, L., Pedata, M., Meli, R., and Calignano, A.
(2011). Potential beneficial effects of butyrate in intestinal and extraintestinal
diseases. World J. Gastroenterol. 17, 1519–1528. doi: 10.3748/wjg.v17.i12.
1519
Cani, P. D., and Van Hul, M. (2015). Novel opportunities for next-generation
probiotics targeting metabolic syndrome. Curr. Opin. Biotechnol. 32, 21–27.
doi: 10.1016/j.copbio.2014.10.006
Chapman, C., Gibson, G., and Rowland, I. (2011). Health benefits of probiotics:
are mixtures more effective than single strains? Eur. J. Nutr. 50, 1–17.
doi: 10.1007/s00394-010-0166-z
Chen, J., Wang, R., Li, X.-F., and Wang, R.-L. (2011). Bifidobacterium adolescentis
supplementation ameliorates visceral fat accumulation and insulin sensitivity in
an experimental model of the metabolic syndrome. Br. J. Nutr. 107, 1429–1434.
doi: 10.1017/s0007114511004491
Clarke, S. F., Murphy, E. F., O’Sullivan, O., Lucey, A. J., Humphreys, M., Hogan, A.,
et al. (2014). Exercise and associated dietary extremes impact on gut microbial
diversity. Gut 63, 1913–1920. doi: 10.1136/gutjnl-2013-306541
Damin, M. R., Minowa, E., Alcântara, M. R., and Oliveira, M. N. (2008). Effect of
cold storage on culture viability and some rheological properties of fermented
milk prepared with yogurt and probiotic bacteria. J. Texture Stud. 39, 40–55.
doi: 10.1111/j.1745-4603.2007.00129.x
Dao, M. C., Everard, A., Aron-Wisnewsky, J., Sokolovska, N., Prifti, E., Verger,
E. O., et al. (2016). Akkermansia muciniphila and improved metabolic
health during a dietary intervention in obesity: relationship with gut
microbiome richness and ecology. Gut 65, 426–436. doi: 10.1136/gutjnl-2014-
308778
De Palma, G., Collins, S. M., and Bercik, P. (2014). The microbiota-gut-brain axis
in functional gastrointestinal disorders. Gut Microbes 5, 419–429. doi: 10.4161/
gmic.29417
De Palma, G., Lynch, M. D. J., Lu, J., Dang, V. T., Deng, Y., Jury, J., et al.
(2017). Transplantation of fecal microbiota from patients with irritable bowel
syndrome alters gut function and behavior in recipient mice. Sci. Transl. Med.
9:eaaf6397. doi: 10.1126/scitranslmed.aaf6397
den Besten, G., van Eunen, K., Groen, A. K., Venema, K., Reijngoud, D.-J., and
Bakker, B. M. (2013). The role of short-chain fatty acids in the interplay between
diet, gut microbiota, and host energy metabolism. J. Lipid Res. 54, 2325–2340.
doi: 10.1194/jlr.r036012
Dethlefsen, L., and Relman, D. A. (2010). Incomplete recovery and individualized
responses of the human distal gut microbiota to repeated antibiotic
perturbation. Proc. Natl. Acad. Sci. U.S.A. 108(Suppl. 1), 4554–4561.
doi: 10.1073/pnas.1000087107
Di Cerbo, A., Palmieri, B., Aponte, M., Morales-Medina, J. C., and Iannitti, T.
(2016). Mechanisms and therapeutic effectiveness of lactobacilli. J. Clin. Pathol.
69, 187–203. doi: 10.1136/jclinpath-2015-202976
Distrutti, E., Monaldi, L., Ricci, P., and Fiorucci, S. (2016). Gut microbiota role in
irritable bowel syndrome: new therapeutic strategies. World J. Gastroenterol. 22,
2219–2241. doi: 10.3748/wjg.v22.i7.2219
EFSA Panel on Biological Hazards (BIOHAZ) (2013). Scientific opinion on the
maintenance of the list of QPS biological agents intentionally added to food
and feed (2013 update). EFSA J. 11:3449. doi: 10.2903/j.efsa.2013.3449
Engels, C., Ruscheweyh, H.-J., Beerenwinkel, N., Lacroix, C., and Schwab, C.
(2016). The common gut microbe Eubacterium hallii also contributes to
intestinal propionate formation. Front. Microbiol. 7:713. doi: 10.3389/fmicb.
2016.00713
Evans, C. T., and Johnson, S. (2015). Prevention of Clostridium difficile infection
with probiotics. Clin. Infect. Dis. 60(Suppl. 2), S122–S128. doi: 10.1093/cid/
civ138
Everard, A., Lazarevic, V., Gaïa, N., Johansson, M., Ståhlman, M., Backhed, F., et al.
(2014). Microbiome of prebiotic-treated mice reveals novel targets involved in
host response during obesity. ISME J. 8, 2116–2130. doi: 10.1038/ismej.2014.45
Frontiers in Microbiology | www.frontiersin.org 8 September 2017 | Volume 8 | Article 1889
fmicb-08-01889 September 27, 2017 Time: 16:55 # 9
El Hage et al. Next Generation Probiotics for Health and Industry
Fernández-Murga, M. L., and Sanz, Y. (2016). Safety assessment of Bacteroides
uniformis CECT 7771 isolated from stools of healthy breast-fed infants. PLOS
ONE 11:e0145503. doi: 10.1371/journal.pone.0145503
Figueroa, I., Johnson, S., Sambol, S. P., Goldstein, E. J. C., Citron, D. M., and
Gerding, D. N. (2012). Relapse versus reinfection: recurrent Clostridium difficile
infection following treatment with fidaxomicin or vancomycin. Clin. Infect. Dis.
55(Suppl. 2), S104–S109. doi: 10.1093/cid/cis357
Francino, M. P. (2016). Antibiotics and the human gut microbiome: dysbioses and
accumulation of resistances. Front. Microbiol. 6:1543. doi: 10.3389/fmicb.2015.
01543
Gauffin Cano, P., Santacruz, A., Moya, Á., and Sanz, Y. (2012). Bacteroides
uniformis CECT 7771 ameliorates metabolic and immunological dysfunction
in mice with high-fat-diet induced obesity. PLOS ONE 7:e41079. doi: 10.1371/
journal.pone.0041079
Gibson, G. R., Hutkins, R., Sanders, M. E., Prescott, S. L., Reimer, R. A., Salminen,
S. J., et al. (2017). Expert consensus document: the international scientific
association for probiotics and prebiotics (ISAPP) consensus statement on the
definition and scope of prebiotics. Nat. Rev. Gastroenterol. Hepatol. 14, 491–502.
doi: 10.1038/nrgastro.2017.75
Goldenberg, J. Z., Ma, S. S. Y., Saxton, J. D., Martzen, M. R., Vandvik, P. O.,
Thorlund, K., et al. (2013). Probiotics for the prevention of Clostridium
difficile-associated diarrhea in adults and children. Cochrane Database Syst. Rev.
doi: 10.1002/14651858.CD006095.pub3
Govender, M., Choonara, Y. E., Kumar, P., du Toit, L. C., van Vuuren, S.,
and Pillay, V. (2013). A review of the advancements in probiotic delivery:
conventional vs. non-conventional formulations for intestinal flora
supplementation. AAPS PharmsciTech 15, 29–43. doi: 10.1208/s12249-
013-0027-1
Graf, D., Di Cagno, R., Fåk, F., Flint, H. J., Nyman, M., Saarela, M., et al. (2015).
Contribution Of diet to the composition of the human gut microbiota. Microb.
Ecol. Health Dis. 26:26164. doi: 10.3402/mehd.v26.26164
Guarner, F., and Malagelada, J.-R. (2003). Gut flora in health and disease. Lancet
361, 512–519. doi: 10.1016/s0140-6736(03)12489-0
Gueimonde, M., and Sánchez, B. (2012). Enhancing probiotic stability in industrial
processes. Microb. Ecol. Health Dis. 23:18562. doi: 10.3402/mehd.v23i0.18562
Hand, T. W. (2016). The role of the microbiota in shaping infectious immunity.
Trends Immunol. 37, 647–658. doi: 10.1016/j.it.2016.08.007
Hartstra, A. V., Bouter, K. E. C., Bäckhed, F., and Nieuwdorp, M. (2015). Insights
into the role of the microbiome in obesity and type 2 diabetes. Diabetes Care 38,
159–165. doi: 10.2337/dc14-0769
Heidebach, T., Först, P., and Kulozik, U. (2012). Microencapsulation of probiotic
cells for food applications. Crit. Rev. Food Sci. Nutr. 52, 291–311. doi: 10.1080/
10408398.2010.499801
Hill, C., Guarner, F., Reid, G., Gibson, G. R., Merenstein, D. J., Pot, B., et al.
(2014). Expert consensus document: the international scientific association for
probiotics and prebiotics consensus statement on the scope and appropriate
use of the term probiotic. Nat. Rev. Gastroenterol. Hepatol. 11, 506–514.
doi: 10.1038/nrgastro.2014.66
Jafarnejad, S., Saremi, S., Jafarnejad, F., and Arab, A. (2016). Effects of a
multispecies probiotic mixture on glycemic control and inflammatory status in
women with gestational diabetes: a randomized controlled clinical trial. J. Nutr.
Metab. 2016:5190846. doi: 10.1155/2016/5190846
Jiang, Z.-D., Hoang, L. N., Lasco, T. M., Garey, K. W., and DuPont, H. L.
(2013). Physician attitudes toward the use of fecal transplantation for recurrent
Clostridium difficile infection in a metropolitan area. Clin. Infect. Dis. 56,
1059–1060. doi: 10.1093/cid/cis1025
Johnson, S., Adelmann, A., Clabots, C. R., Peterson, L. R., and Gerding, D. N.
(1989). Recurrences of Clostridium difficile diarrhea not caused by the original
infecting organism. J. Infect. Dis. 159, 340–343. doi: 10.1093/infdis/159.2.340
Kasin´ska, M. A., and Drzewoski, J. (2015). Effectiveness of probiotics in Type 2
diabetes: a meta-analysis. Pol. Arch. Intern. Med. 125, 803–813. doi: 10.20452/
pamw.3156
Kelly, C. P. (2009). A 76-year-old man with recurrent Clostridium
difficile–associated diarrhea. JAMA 301, 954–962. doi: 10.1001/jama.200
9.171
Kelly, C. P. (2013). Fecal microbiota transplantation—an old therapy comes of age.
N. Engl. J. Med. 368, 474–475. doi: 10.1056/nejme1214816
Khanna, S., Pardi, D. S., Kelly, C. R., Kraft, C. S., Dhere, T., Henn, M. R., et al.
(2016). A novel microbiome therapeutic increases gut microbial diversity and
prevents recurrent Clostridium difficile infection. J. Infect. Dis. 214, 173–181.
doi: 10.1093/infdis/jiv766
Kim, S.-W., Park, K.-Y., Kim, B., Kim, E., and Hyun, C.-K. (2013). Lactobacillus
rhamnosus GG improves insulin sensitivity and reduces adiposity in high-
fat diet-fed mice through enhancement of adiponectin production. Biochem.
Biophys. Res. Commun. 431, 258–263. doi: 10.1016/j.bbrc.2012.12.121
Klaenhammer, T. R., Kleerebezem, M., Kopp, M. V., and Rescigno, M. (2012). The
impact of probiotics and prebiotics on the immune system. Nat. Rev. Immunol.
12, 728–734. doi: 10.1038/nri3312
Kobyliak, N., Conte, C., Cammarota, G., Haley, A. P., Styriak, I., Gaspar, L., et al.
(2016). Probiotics in prevention and treatment of obesity: a critical view. Nutr.
Metab. 13, 14. doi: 10.1186/s12986-016-0067-0
Koning, C. J., Jonkers, D. M., Stobberingh, E. E., Mulder, L., Rombouts, F. M.,
and Stockbrügger, R. W. (2008). The effect of a multispecies probiotic on the
intestinal microbiota and bowel movements in healthy volunteers taking the
antibiotic amoxycillin. Am. J. Gastroenterol. 103, 178–189. doi: 10.1111/j.1572-
0241.2007.01547.x
Kristensen, N. B., Bryrup, T., Allin, K. H., Nielsen, T., Hansen, T. H., and
Pedersen, O. (2016). Alterations in fecal microbiota composition by probiotic
supplementation in healthy adults: a systematic review of randomized
controlled trials. Genome Med. 8, 52. doi: 10.1186/s13073-016-0300-5
Kwon, H.-K., Lee, C.-G., So, J.-S., Chae, C.-S., Hwang, J.-S., Sahoo, A., et al. (2010).
Generation of regulatory dendritic cells and CD4+Foxp3+ T cells by probiotics
administration suppresses immune disorders. Proc. Natl. Acad. Sci. U.S.A. 107,
2159–2164. doi: 10.1073/pnas.0904055107
Langdon, A., Crook, N., and Dantas, G. (2016). The effects of antibiotics on
the microbiome throughout development and alternative approaches for
therapeutic modulation. Genome Med. 8:39. doi: 10.1186/s13073-016-0294-z
Leszczyszyn, J. J., Radomski, M., and Leszczyszyn, A. M. (2016). Intestinal
microbiota transplant – current state of knowledge. Reumatologia 54, 24–28.
doi: 10.5114/reum.2016.58758
Li, J., Lin, S., Vanhoutte, P. M., Woo, C. W., and Xu, A. (2016). Akkermansia
muciniphila protects against atherosclerosis by preventing metabolic
endotoxemia-induced inflammation in apoe-/-mice clinical. Circulation
133, 2434–2446. doi: 10.1161/circulationaha.115.019645
Lowes, R. (2016). FDA Proposes Tighter Rules For Fecal Transplants. New York, NY:
Medscape.
Macpherson, A. J., de Agüero, M. G., and Ganal-Vonarburg, S. C. (2017). How
nutrition and the maternal microbiota shape the neonatal immune system. Nat.
Rev. Immunol. 17, 508–517. doi: 10.1038/nri.2017.58
Marotz, C. A., and Zarrinpar, A. (2016). Treating obesity and metabolic syndrome
with fecal microbiota transplantation. Yale J. Biol. Med. 89, 383–388.
Marsh, J. W., Arora, R., Schlackman, J. L., Shutt, K. A., Curry, S. R., and
Harrison, L. H. (2012). Association of relapse of Clostridium difficile disease
with BI/NAP1/027. J. Clin. Microbiol. 50, 4078–4082. doi: 10.1128/jcm.
02291-12
Martín, R., Chain, F., Miquel, S., Lu, J., Gratadoux, J.-J., Sokol, H., et al. (2014).
The commensal bacterium Faecalibacterium prausnitzii is protective in DNBS-
induced chronic moderate and severe colitis models. Inflamm. Bowel Dis. 20,
417–430. doi: 10.1097/01.mib.0000440815.76627.64
Martín, R., Miquel, S., Benevides, L., Bridonneau, C., Robert, V., Hudault, S.,
et al. (2017). Functional characterization of novel Faecalibacterium prausnitzii
strains isolated from healthy volunteers: a step forward in the use of
F. prausnitzii as a next-generation probiotic. Front. Microbiol. 8:1226.
doi: 10.3389/fmicb.2017.01226
Miettinen, M., Vuopio-Varkila, J., and Varkila, K. (1996). Production of human
tumor necrosis factor alpha, interleukin-6, and interleukin-10 is induced by
lactic acid bacteria. Infect. Immun. 64, 5403–5405.
Miquel, S., Leclerc, M., Martin, R., Chain, F., Lenoir, M., Raguideau, S., et al. (2015).
Identification of metabolic signatures linked to anti-inflammatory effects of
Faecalibacterium prausnitzii. mBio 6:e00300-15. doi: 10.1128/mbio.00300-15
Moayyedi, P., Surette, M. G., Kim, P. T., Libertucci, J., Wolfe, M., Onischi, C.,
et al. (2015). Fecal microbiota transplantation induces remission in patients
with active ulcerative colitis in a randomized controlled trial. Gastroenterology
149, 102.e6–109.e6. doi: 10.1053/j.gastro.2015.04.001
Frontiers in Microbiology | www.frontiersin.org 9 September 2017 | Volume 8 | Article 1889
fmicb-08-01889 September 27, 2017 Time: 16:55 # 10
El Hage et al. Next Generation Probiotics for Health and Industry
Nazemian, V., Shadnoush, M., Manaheji, H., and Zaringhalam, J. (2016). Probiotics
and inflammatory pain: a literature review study. Middle East J. Rehabil. Health
Stud. 3:e36087. doi: 10.17795/mejrh-36087
Neef, A., and Sanz, Y. (2013). Future for probiotic science in functional food
and dietary supplement development. Curr. Opin. Clin. Nutr. Metab. Care 16,
679–687. doi: 10.1097/mco.0b013e328365c258
Ng, S. C., Hart, A. L., Kamm, M. A., Stagg, A. J., and Knight, S. C. (2009).
Mechanisms of action of probiotics: recent advances. Inflamm. Bowel Dis. 15,
300–310. doi: 10.1002/ibd.20602
Orenstein, R., Dubberke, E., Hardi, R., Ray, A., Mullane, K., Pardi, D. S., et al.
(2015). Safety and durability of RBX2660 (microbiota suspension) for recurrent
Clostridium difficile infection: results of the PUNCH CD study. Clin. Infect. Dis.
62, 596–602. doi: 10.1093/cid/civ938
Patel, R., and DuPont, H. L. (2015). New approaches for bacteriotherapy:
prebiotics, new-generation probiotics, and synbiotics. Clin. Infect. Dis.
60(Suppl. 2), S108–S121. doi: 10.1093/cid/civ177
Patrascu, O., Béguet-Crespel, F., Marinelli, L., Le Chatelier, E., Abraham, A. L.,
Leclerc, M., et al. (2017). A fibrolytic potential in the human ileum mucosal
microbiota revealed by functional metagenomic. Sci. Rep. 7:40248. doi: 10.1038/
srep40248
Pattani, R., Palda, V. A., Hwang, S. W., and Shah, P. S. (2013). Probiotics for the
prevention of antibiotic-associated diarrhea and Clostridium difficile infection
among hospitalized patients: systematic review and meta-analysis. Open Med.
7, 56–67.
Paulo Sousa e Silva, J., and Freitas, A. C. (2014). Probiotic Bacteria, 1st Edn.
Singapore: Pan Stanford Publishing.
Pérez-Cobas, A., Moya, A., Gosalbes, M., and Latorre, A. (2015). Colonization
resistance of the gut microbiota against Clostridium difficile. Antibiotics 4,
337–357. doi: 10.3390/antibiotics4030337
Petrof, E. O., Gloor, G. B., Vanner, S. J., Weese, S. J., Carter, D., Daigneault,
M. C., et al. (2013). Stool substitute transplant therapy for the eradication
of Clostridium difficile infection: ‘RePOOPulating’ the gut. Microbiome 1:3.
doi: 10.1186/2049-2618-1-3
Pharmabiotic Research Institute (2017). PRI: Microbiotic Medicinal Products.
Available at: http://www.pharmabiotic.org/
Pigneur, B., and Sokol, H. (2016). Fecal microbiota transplantation in inflammatory
bowel disease: the quest for the holy grail. Mucosal Immunol. 9, 1360–1365.
doi: 10.1038/mi.2016.67
Pinto-Sanchez, M. I., Hall, G. B., Ghajar, K., Nardelli, A., Bolino, C., Lau, J. T.,
et al. (2017). Probiotic Bifidobacterium longum NCC3001 reduces depression
scores and alters brain activity: a pilot study in patients with irritable bowel
syndrome. Gastroenterology 153, 448.e8–459.e8. doi: 10.1053/j.gastro.2017.
05.003
Plaza-Diaz, J. (2014). Modulation of immunity and inflammatory gene expression
in the gut, in inflammatory diseases of the gut and in the liver by probiotics.
World J. Gastroenterol. 20:15632. doi: 10.3748/wjg.v20.i42.15632
Plaza-Diaz, J., Gomez-Llorente, C., Abadia-Molina, F., Saez-Lara, M. J., Campaña-
Martin, L., Muñoz-Quezada, S., et al. (2014). Effects of Lactobacillus paracasei
CNCM I-4034, Bifidobacterium breve CNCM I-4035 and Lactobacillus
rhamnosus CNCM I-4036 on hepatic steatosis in zucker rats. PLOS ONE
9:e98401. doi: 10.1371/journal.pone.0098401
Quévrain, E., Maubert, M. A., Michon, C., Chain, F., Marquant, R., Tailhades,
J., et al. (2016). Identification of an anti-inflammatory protein from
Faecalibacterium prausnitzii, a commensal bacterium deficient in Crohn’s
disease. Gut 65, 415–425. doi: 10.1136/gutjnl-2014-307649
Ramesh, M., Khanna, S., Messer, J., and Adams, M. (2016). Prevention of Recurrent
C. difficile Infection with RBX2660 | PUNCH CD 2 Results. Roseville, MN:
Rebiotix.
Rao, K., and Safdar, N. (2015). Fecal microbiota transplantation for the treatment
of Clostridium difficile infection. J. Hosp. Med. 11, 56–61. doi: 10.1002/jhm.
2449
Rao, K., and Young, V. B. (2017). Probiotics for prevention of Clostridium difficile
infection in hospitalized patients: is the jury still out? Gastroenterology 152,
1817–1819. doi: 10.1053/j.gastro.2017.04.027
Ratner, M. (2015). Microbial cocktails join fecal transplants in IBD treatment trials.
Nat. Biotechnol. 33, 787–788. doi: 10.1038/nbt0815-787
Reardon, S. (2014). Microbiome therapy gains market traction. Nature 509,
269–270. doi: 10.1038/509269a
Rebiotix Media (2015). Rebiotix Receives Breakthrough Therapy Designation
for RBX2660 – A Microbiota Restoration Therapy (MRT) for the
Treatment of Recurrent Clostridium difficile Infection. Available at:
http://www.rebiotix.com/wp-content/uploads/rebiotix_receives_
breakthrough_therapy_designation_recurrent_clostridium_difficile.pdf
Reichold, A., Brenner, S. A., Spruss, A., Förster-Fromme, K., Bergheim, I.,
and Bischoff, S. C. (2014). Bifidobacterium adolescentis protects from the
development of nonalcoholic steatohepatitis in a mouse model. J. Nutr.
Biochem. 25, 118–125. doi: 10.1016/j.jnutbio.2013.09.011
Reijnders, D., Goossens, G. H., Hermes, G. D., Neis, E. P., van der Beek, C. M.,
Most, J., et al. (2016). Effects of gut microbiota manipulation by antibiotics
on host metabolism in obese humans: a randomized double-blind placebo-
controlled trial. Cell Metab. 24, 63–74. doi: 10.1016/j.cmet.2016.07.008
Ricci, A., Allende, A., Bolton, D., Chemaly, M., Davies, R., Girones, R., et al. (2017).
Update of the list of QPS-recommended biological agents intentionally added
to food or feed as notified to EFSA 5: suitability of taxonomic units notified to
EFSA until September 2016. EFSA J. 15:4663. doi: 10.2903/j.efsa.2017.4663
Rivière, A., Selak, M., Lantin, D., Leroy, F., and De Vuyst, L. (2016). Bifidobacteria
and butyrate-producing colon bacteria: importance and strategies for their
stimulation in the human gut. Front. Microbiol. 7:979. doi: 10.3389/fmicb.2016.
00979
Round, J. L., Lee, S. M., Li, J., Tran, G., Jabri, B., Chatila, T. A., et al. (2011). The toll-
like receptor 2 pathway establishes colonization by a commensal of the human
microbiota. Science 332, 974–977. doi: 10.1126/science.1206095
Round, J. L., and Mazmanian, S. K. (2009). The gut microbiota shapes intestinal
immune responses during health and disease. Nat. Rev. Immunol. 9, 600–600.
doi: 10.1038/nri2614
Sanders, M. E. (2008). Probiotics: definition, sources, selection, and uses. Clin.
Infect. Dis. 46, S58–S61. doi: 10.1086/523341
Sang, L.-X. (2010). Remission induction and maintenance effect of probiotics on
ulcerative colitis: a meta-analysis. World J. Gastroenterol. 16:1908. doi: 10.3748/
wjg.v16.i15.1908
Saulnier, D. M., Ringel, Y., Heyman, M. B., Foster, J. A., Bercik, P., Shulman,
R. J., et al. (2013). The intestinal microbiome, probiotics and prebiotics in
neurogastroenterology. Gut Microbes 4, 17–27. doi: 10.4161/gmic.22973
Savcheniuk, O., Kobyliak, N., Kondro, M., Virchenko, O., Falalyeyeva, T., and
Beregova, T. (2014). Short-term periodic consumption of multiprobiotic
from childhood improves insulin sensitivity, prevents development of non-
alcoholic fatty liver disease and adiposity in adult rats with glutamate-induced
obesity. BMC Complement. Altern. Med. 14:247. doi: 10.1186/1472-6882-
14-247
Sbahi, H., and Di Palma, J. A. (2016). Faecal microbiota transplantation:
applications and limitations in treating gastrointestinal disorders. BMJ Open
Gastroenterol. 3:e000087. doi: 10.1136/bmjgast-2016-000087
Schneeberger, M., Everard, A., Gómez-Valadés, A. G., Matamoros, S., Ramírez, S.,
Delzenne, N. M., et al. (2015). Akkermansia muciniphila inversely correlates
with the onset of inflammation, altered adipose tissue metabolism and
metabolic disorders during obesity in mice. Sci. Rep. 5:16643. doi: 10.1038/
srep16643
Scott, K. P., Antoine, J. M., Midtvedt, T., and van Hemert, S. (2015). Manipulating
the gut microbiota to maintain health and treat disease. Microb. Ecol. Health
Dis. 26:25877. doi: 10.3402/mehd.v26.25877
Seres Therapeutics (2015). Seres Therapeutics, Inc. Announces FDA Orphan Drug
Designation for SER-109 for the Prevention of Recurrent Clostridium difficile
Infection in Adults. Available at: http://ir.serestherapeutics.com/phoenix.zhtml?
c=254006&p=irol-newsArticle&ID=2081167
Seres Therapeutics (2017). Inflammatory Bowel Disease. Serestherapeutics.Com.
Available at: http://www.serestherapeutics.com/pipeline/products/
inflammatory-bowel-disease
Shah, N. P., Ding, W. K., Fallourd, M. J., and Leyer, G. (2010). Improving
the stability of probiotic bacteria in model fruit juices using vitamins and
antioxidants. J. Food Sci. 75, M278–M282. doi: 10.1111/j.1750-3841.2010.
01628.x
Shi, Y., Dong, Y., Huang, W., Zhu, D., Mao, H., and Su, P. (2016). Fecal microbiota
transplantation for ulcerative colitis: a systematic review and meta-analysis.
PLOS ONE 11:e0157259. doi: 10.1371/journal.pone.0157259
Sokol, H., Galperine, T., Kapel, N., Bourlioux, P., Seksik, P., Barbut, F., et al. (2016).
Faecal microbiota transplantation in recurrent Clostridium difficile infection:
Frontiers in Microbiology | www.frontiersin.org 10 September 2017 | Volume 8 | Article 1889
fmicb-08-01889 September 27, 2017 Time: 16:55 # 11
El Hage et al. Next Generation Probiotics for Health and Industry
recommendations from the French group of faecal microbiota transplantation.
Dig. Liver Dis. 48, 242–247. doi: 10.1016/j.dld.2015.08.017
Sokol, H., Pigneur, B., Watterlot, L., Lakhdari, O., Bermudez-Humaran, L. G.,
Gratadoux, J.-J., et al. (2008). Faecalibacterium prausnitzii is an anti-
inflammatory commensal bacterium identified by gut microbiota analysis
of Crohn disease patients. Proc. Natl. Acad. Sci. U.S.A. 105, 16731–16736.
doi: 10.1073/pnas.0804812105
Steenbergen, L., Sellaro, R., van Hemert, S., Bosch, J. A., and Colzato, L. S. (2015).
A randomized controlled trial to test the effect of multispecies probiotics
on cognitive reactivity to sad mood. Brain Behav. Immun. 48, 258–264.
doi: 10.1016/j.bbi.2015.04.003
Surawicz, C. M., Brandt, L. J., Binion, D. G., Ananthakrishnan, A. N., Curry, S. R.,
Gilligan, P. H., et al. (2013). Guidelines for diagnosis, treatment, and prevention
of Clostridium difficile infections. Am. J. Gastroenterol. 108, 478–498.
doi: 10.1038/ajg.2013.4
Timmerman, H. M., Koning, C. J. M., Mulder, L., Rombouts, F. M., and
Beynen, A. C. (2004). Monostrain, multistrain and multispecies probiotics—a
comparison of functionality and efficacy. Int. J. Food Microbiol. 96, 219–233.
doi: 10.1016/j.ijfoodmicro.2004.05.012
Timmerman, H. M., Niers, L. E. M., Ridwan, B. U., Koning, C. J. M., Mulder, L.,
Akkermans, L. M. A., et al. (2007). Design of a multispecies probiotic mixture
to prevent infectious complications in critically ill patients. Clin. Nutr. 26,
450–459. doi: 10.1016/j.clnu.2007.04.008
Troy, E. B., and Kasper, D. L. (2010). Beneficial effects of Bacteroides fragilis
polysaccharides on the immune system. Front. Biosci. 15, 25–34. doi: 10.2741/
3603
Udayappan, S., Manneras-Holm, L., Chaplin-Scott, A., Belzer, C., Herrema, H.,
Dallinga-Thie, G.-M., et al. (2016). Oral treatment with Eubacterium hallii
improves insulin sensitivity in db/db mice. NPJ Biofilms Microbiomes 2:16009.
doi: 10.1038/npjbiofilms.2016.9
van der Lelie, D., Taghavi, S., Henry, C., and Gilbert, J. A. (2017). The microbiome
as a source of new enterprises and job creation: considering clinical faecal
and synthetic microbiome transplants and therapeutic regulation. Microb.
Biotechnol. 10, 4–5. doi: 10.1111/1751-7915.12597
van Minnen, L. P., Timmerman, H. M., Lutgendorff, F., Verheem, A., Harmsen, W.,
Konstantinov, S. R., et al. (2007). Modification of intestinal flora with
multispecies probiotics reduces bacterial translocation and improves clinical
course in a rat model of acute pancreatitis. Surgery 141, 470–480. doi: 10.1016/
j.surg.2006.10.007
van Nood, E., Speelman, P., Nieuwdorp, M., and Keller, J. (2014). Fecal Microbiota
Transplantation. New York, NY: Medscape.
Venturi, A., Gionchetti, P., Rizzello, F., Johansson, R., Zucconi, E., Brigidi, P.,
et al. (1999). Impact on the composition of the faecal flora by a new probiotic
preparation: preliminary data on maintenance treatment of patients with
ulcerative colitis. Aliment. Pharmacol. Ther. 13, 1103–1108. doi: 10.1046/j.1365-
2036.1999.00560.x
Vermeire, S., Joossens, M., Verbeke, K., Wang, J., Machiels, K., Sabino, J., et al.
(2015). Donor species richness determines faecal microbiota transplantation
success in inflammatory bowel disease. J. Crohns Colitis 10, 387–394.
doi: 10.1093/ecco-jcc/jjv203
Wallace, C. J. K., and Milev, R. (2017). The effects of probiotics on depressive
symptoms in humans: a systematic review. Ann. Gen. Psychiatry 16, 14.
doi: 10.1186/s12991-017-0141-7
Wang, J., Tang, H., Zhang, C., Zhao, Y., Derrien, M., Rocher, E., et al. (2014).
Modulation of gut microbiota during probiotic-mediated attenuation of
metabolic syndrome in high fat diet-fed mice. ISME J. 9, 1–15. doi: 10.1038/
ismej.2014.99
Wexler, H. M. (2007). Bacteroides: the good, the bad, and the nitty-gritty. Clin.
Microbiol. Rev. 20, 593–621. doi: 10.1128/cmr.00008-07
WHO/FAO (2006). Probiotics in Food Health and Nutritional Properties and
Guidelines for Evaluation. Rome: Food and Agriculture Organization of the
United Nations.
Yan, F., and Polk, D. B. (2011). Probiotics and immune health. Curr. Opin.
Gastroenterol. 27, 496–501. doi: 10.1097/mog.0b013e32834baa4d
Yang, J.-Y., Lee, Y.-S., Kim, Y., Lee, S.-H., Ryu, S., Fukuda, S., et al. (2016).
Gut Commensal Bacteroides acidifaciens prevents obesity and improves insulin
sensitivity in mice. Mucosal Immunol. 10, 104–116. doi: 10.1038/mi.2016.42
Yin, Y.-N. (2010). Effects of four Bifidobacteria on obesity in high-fat diet
induced rats. World J. Gastroenterol. 16:3394. doi: 10.3748/wjg.v16.i27.
3394
Yoon, J. S., Sohn, W., Lee, O. Y., Lee, S. P., Lee, K. N., Jun, D. W., et al. (2013).
Effect of multispecies probiotics on irritable bowel syndrome: a randomized,
double-blind, placebo-controlled trial. J. Gastroenterol. Hepatol. 29, 52–59.
doi: 10.1111/jgh.12322
Youngster, I., Russell, G., Pindar, C., Sauk, J., and Hohmann, E. (2014).
1798Oral, frozen fecal microbiota capsules for relapsing Clostridium difficile
infection. Open Forum Infect. Dis. 1(Suppl. 1), S62–S62. doi: 10.1093/ofid/
ofu051.170
Zhou, D. (2016). Impact of sanitary living environment on gut microbiota. Precis.
Med. 2:e1161. doi: 10.14800/pm.1161
Zipursky, J. S., Sidorsky, T. I., Freedman, C. A., Sidorsky, M. N., and Kirkland, K. B.
(2014). Patient attitudes toward the use of fecal microbiota transplantation in
the treatment of recurrent Clostridium difficile infection. Clin. Infect. Dis. 55,
1652–1658. doi: 10.1093/cid/cis809
Conflict of Interest Statement: The authors declare that the research was
conducted in the absence of any commercial or financial relationships that could
be construed as a potential conflict of interest.
Copyright © 2017 El Hage, Hernandez-Sanabria and Van de Wiele. This is an
open-access article distributed under the terms of the Creative Commons Attribution
License (CC BY). The use, distribution or reproduction in other forums is permitted,
provided the original author(s) or licensor are credited and that the original
publication in this journal is cited, in accordance with accepted academic practice.
No use, distribution or reproduction is permitted which does not comply with these
terms.
Frontiers in Microbiology | www.frontiersin.org 11 September 2017 | Volume 8 | Article 1889
